Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600
Debt
Debt-to-Equity RatioN/A
Current Ratio28.23
Quick Ratio28.23
Price-To-Earnings
Trailing P/E Ratio14.03
Forward P/E Ratio8.61
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.22 million
Price / Sales7.65
Cash Flow$1.5041 per share
Price / Cash10.93
Book Value($2.38) per share
Price / Book-6.91
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins75.67%
Return on Equity-110.01%
Return on Assets62.76%
Miscellaneous
Employees12
Outstanding Shares101,040,000
Market Cap$1.66 billion
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, October, 31st. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.49 by $0.06. The biotechnology company earned $61.70 million during the quarter, compared to the consensus estimate of $64 million. Innoviva had a negative return on equity of 110.01% and a net margin of 75.67%. The firm's quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.21 earnings per share. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
3 analysts have issued 1-year target prices for Innoviva's stock. Their predictions range from $13.00 to $16.00. On average, they anticipate Innoviva's share price to reach $14.50 in the next year. This suggests that the stock has a possible downside of 11.8%. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Innoviva.
Has Innoviva been receiving favorable news coverage?
Press coverage about INVA stock has been trending somewhat positive on Tuesday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Innoviva earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), Nektar Therapeutics (NKTR), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO) and Agios Pharmaceuticals (AGIO).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Ms. Marianne Zhen, Chief Accounting Officer & Principal Accounting Officer (Age 49)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
- Dr. Edmund J. Moran Ph.D., VP and R&D Program Leader (Age 57)
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.71%), Dimensional Fund Advisors LP (2.12%), LSV Asset Management (1.76%), First Eagle Investment Management LLC (1.56%), MERIAN GLOBAL INVESTORS UK Ltd (1.44%) and Wells Fargo & Company MN (1.37%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Which institutional investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, First Trust Advisors LP, James Investment Research Inc., American Century Companies Inc., Hussman Strategic Advisors Inc., NJ State Employees Deferred Compensation Plan, Pictet Asset Management Ltd. and Victory Capital Management Inc.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which institutional investors are buying Innoviva stock?
INVA stock was bought by a variety of institutional investors in the last quarter, including LSV Asset Management, JPMorgan Chase & Co., WINTON GROUP Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Schroder Investment Management Group, BlackRock Inc., First Eagle Investment Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $16.44.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.66 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
